IMCIVREE Wins FDA Approval for Acquired Hypothalamic Obesity
FDA approved setmelanotide (IMCIVREE), an MC4R agonist peptide, for reducing body weight in adults and children aged 4+. Phase 3 TRANSCEND trial showed 18.4% placebo-adjusted BMI reduction at 52 weeks.